We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
+$6.44M
Cap. Flow
-$803K
Cap. Flow %
-0.33%
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11

Top Buys

Rank Stock Value
1
BKCC
BlackRock Capital Investment Corporation
BKCC
+$673K
2
ZLAB icon
Zai Lab
ZLAB
+$472K
3
SCM icon
Stellus Capital Investment Corp
SCM
+$422K
4
DRD
DRDGold
DRD
+$415K
5
OXLC
Oxford Lane Capital
OXLC
+$359K

Top Sells

Rank Stock Value
1
AMRS
Amyris Inc.
AMRS
+$1.16M
2
RUBY
Rubius Therapeutics, Inc
RUBY
+$664K
3
BNTX icon
BioNTech
BNTX
+$663K
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$645K
5
PRTA icon
Prothena Corp
PRTA
+$590K

Sector Composition

Rank Sector Weight
1 Healthcare 27.38%
2 Real Estate 18.81%
3 Energy 13.29%
4 Materials 10.7%
5 Utilities 10.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBIO
201
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$290K 0.12%
10,536
-624
-6% -$12.3K
MGNX icon
202
MacroGenics
MGNX
$235M
$289K 0.12%
10,754
-1,894
-15% -$55.5K
CRSP icon
203
CRISPR Therapeutics
CRSP
$4.58B
$281K 0.12%
1,737
-266
-13% -$32.4K
CLDX icon
204
Celldex Therapeutics
CLDX
$2.77B
$278K 0.11%
8,300
-8,164
-50% -$224K
NKTX icon
205
Nkarta
NKTX
$162M
$264K 0.11%
8,337
+4,026
+93% +$116K
NBP
206
NovaBridge Biosciences American Depositary Shares
NBP
$205M
$259K 0.11%
3,086
-4,774
-61% -$315K
MCRB icon
207
Seres Therapeutics
MCRB
$48M
$258K 0.11%
541
-64
-11% -$27K
FLNA
208
Filana Therapeutics
FLNA
$43M
$252K 0.1%
+2,951
New +$158K
INBX
209
DELISTED
Inhibrx, Inc. Common Stock
INBX
$252K 0.1%
9,153
+1,885
+26% +$39.3K
RCUS icon
210
Arcus Biosciences
RCUS
$3.57B
$250K 0.1%
9,111
-237
-3% -$6.77K
FIV
211
DELISTED
First Trust Senior Floating Rate 2022 Target Term Fund Common Shares of Beneficial Interest
FIV
$250K 0.1%
26,230
+6,818
+35% +$64.3K
CCAP icon
212
Crescent Capital BDC
CCAP
$399M
$249K 0.1%
13,248
+3,357
+34% +$62.2K
QNCX icon
213
Quince Therapeutics
QNCX
$17.5M
$249K 0.1%
24
-26
-52% -$218K
REPL icon
214
Replimune Group
REPL
$814M
$248K 0.1%
6,452
-435
-6% -$14.9K
KOD icon
215
Kodiak Sciences
KOD
$2.59B
$245K 0.1%
2,636
+328
+14% +$31.5K
DVAX
216
DELISTED
Dynavax Technologies
DVAX
$244K 0.1%
24,799
-33,291
-57% -$303K
IOVA icon
217
Iovance Biotherapeutics
IOVA
$2.23B
$244K 0.1%
9,371
+3,400
+57% +$88.4K
PTGX icon
218
Protagonist Therapeutics
PTGX
$8.75B
$244K 0.1%
5,441
-8,905
-62% -$294K
CARM
219
DELISTED
Carisma Therapeutics
CARM
$243K 0.1%
+2,632
New +$168K
PSTX
220
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$243K 0.1%
+24,287
New +$217K
DTIL icon
221
Precision BioSciences
DTIL
$188M
$241K 0.1%
642
-604
-48% -$181K
PRTA icon
222
Prothena Corp
PRTA
$458M
$241K 0.1%
4,694
-18,904
-80% -$590K
ACIU icon
223
AC Immune
ACIU
$227M
$239K 0.1%
+30,187
New +$209K
AGEN
224
Agenus
AGEN
$249M
$239K 0.1%
2,217
-1,952
-47% -$146K
RLAY icon
225
Relay Therapeutics
RLAY
$4.02B
$239K 0.1%
6,544
-305
-4% -$10.1K
7 8
9
10 11

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q2 2021 Portfolio in Review

As of Q2 2021, Virtus ETF Advisers held 410 positions worth $243M, up 2.7% from $237M the previous quarter. Its ten largest holdings account for 7.7% of the portfolio.

Virtus ETF Advisers's Q2 2021 filing shows 55 new, 156 increased, 186 reduced and 11 closed positions. Its largest new stake was Zai Lab: 2,937 shares worth $520K. The largest sale was Amyris Inc., an estimated $1.16M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 30% a quarter earlier, followed by Real Estate and Energy.

  • Virtus ETF Advisers's largest Q2 2021 buy was Zai Lab: 2,937 shares worth $520K.
  • Virtus ETF Advisers added most to BlackRock Capital Investment Corporation in Q2 2021, an estimated $673K increase.
  • Virtus ETF Advisers's biggest Q2 2021 reduction was Amyris Inc., cutting an estimated $1.16M.
  • Virtus ETF Advisers fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $645K.
  • Virtus ETF Advisers's ten largest holdings make up 7.7% of its $243M portfolio in Q2 2021.
  • Virtus ETF Advisers opened 55 new positions and closed 11 in Q2 2021.
  • Virtus ETF Advisers's portfolio value rose 2.7% quarter-over-quarter to $243M.

Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.